Biodexa Pharmaceuticals annual return on assets (roa)
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Return on Assets (ROA) Growth & History (BDRX)
Biodexa Pharmaceuticals's return on assets (roa) was −38.74% for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −38.74% | +6.51 pp |
| 2024 | 2024-12-31 | −45.25% | +42.87 pp |
| 2023 | 2023-12-31 | −88.12% | −5.07 pp |
| 2022 | 2022-12-31 | −83.05% | −35.00 pp |
| 2021 | 2021-12-31 | −48.04% | +60.96 pp |
| 2020 | 2020-12-31 | −109.00% | −69.72 pp |
| 2019 | 2019-12-31 | −39.29% | +3.86 pp |
| 2018 | 2018-12-31 | −43.15% | −12.81 pp |
| 2017 | 2017-12-31 | −30.33% | +3.07 pp |
| 2016 | 2016-12-31 | −33.40% | — |
Biodexa Pharmaceuticals return on assets (roa) trends
Over the last five fiscal years, Biodexa Pharmaceuticals's return on assets (roa) increased from −109.00% to −38.74%, a change of +70.27 percentage points.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...